Literature DB >> 10760378

Serum iron and ferritin in acute neuroleptic akathisia.

M Hofmann1, E Seifritz, C Botschev, K Kräuchi, F Müller-Spahn.   

Abstract

Acute akathisia is a common and disturbing side effect of classic antipsychotic medication. Some evidence suggests a role for iron deficiency in chronic and tardive akathisia. In acute akathisia, however, the data are contradictory. Serum iron and ferritin levels of 33 inpatients with acute akathisia during classic neuroleptic medication were compared with those of 23 patients on classic neuroleptics without this side effect. Akathisia was rated by means of the Hillside Akathisia Scale. The groups were balanced for age (mean 38.5+/-14.5), medication (butyrophenone- and phenothiazine-derived neuroleptics) and diagnosis (schizophrenia, schizoaffective disorder, psychotic affective disorder). Patients with acute akathisia had significantly lower serum ferritin levels than the patients in the control group. However, the ferritin (56. 94+/-39.54 ng/ml) and iron (88.52+/-40.0 mg/dl) levels in these patients were within the normal range (ferritin 30-300 ng/dl, iron 80-180 mg/dl). No correlations between serum iron or ferritin and akathisia ratings could be found. Although some reduction in serum ferritin was found in patients with acute akathisia compared to patients without akathisia, the difference was small and the ferritin levels were within the range of the normal population. These findings suggest a minor role for iron deficiency in acute akathisia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760378     DOI: 10.1016/s0165-1781(00)00115-3

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Acute Drug-Induced Symptoms of Restless Legs Syndrome in an Emergency Department: What's in a Name?

Authors:  Robert C Stowe
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

2.  Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.

Authors:  Chadi A Calarge; Daryl J Murry; Ekhard E Ziegler; L Eugene Arnold
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-19       Impact factor: 2.576

3.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

4.  Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.

Authors:  Bunta Yoshimura; Kojiro Sato; Shinji Sakamoto; Masaru Tsukahara; Yusaku Yoshimura; Ryuhei So
Journal:  Psychopharmacology (Berl)       Date:  2018-11-15       Impact factor: 4.530

5.  Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder.

Authors:  Sung-Wan Kim; Robert Stewart; Woo-Young Park; Min Jhon; Ju-Yeon Lee; Seon-Young Kim; Jae-Min Kim; Paul Amminger; Young-Chul Chung; Jin-Sang Yoon
Journal:  Nutrients       Date:  2018-11-08       Impact factor: 5.717

Review 6.  The Other Obesity Epidemic-Of Drugs and Bugs.

Authors:  Adonis Sfera; Carolina Osorio; Eddie Lee Diaz; Gerald Maguire; Michael Cummings
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-31       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.